Saudi Chemical (2070) Financial Ratio Screen
Follow screening changes
Email alerts are not currently available. Bookmark this page and check the financial period and retrieval date when reviewing a result.
MSCI new-inclusion financial-ratio snapshot
2070 financial screening at a glance
Calculation date: 2026-10-15. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - Specialty & Generic) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments. The company is involved in the sale, marketing, and distribution of pharmaceutical, veterinary, medical equipment, and cosmetics products; and operates and maintains a secondary care hospital. In addition, it manufactures human medicines, and wholesales and retails of medicines and related products. Further, the company engages in the research and development of medical science activities, and investment business in related industries. The company was incorporated in 1986 and is headquartered in Buraydah, the Kingdom of Saudi Arabia.
Sources to verify: Secondary company profile and classification · Issuer website
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style debt and cash reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 32.8% / 30% | 8.8% / 30% | 31.6% / 30% | 0.77% / 5% | RATIOS FAIL* |
| FTSE | 32.8% / 33% | 8.8% / 33% | 31.6% / 50% | 0.77% / 5% | FINANCIAL SCREEN PASSED* |
Financial Highlights
Profitability
| Gross Margin | 50.3% | |
| Operating Margin | 17.5% | |
| Net Margin | 12.3% | |
| Return on Equity (ROE) | 12.7% | |
| Return on Assets (ROA) | 3.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | SAR 272M |
| Free Cash Flow | SAR 173M |
| Total Debt | SAR 1.4B |
| Debt-to-Equity | 78.6 |
| Current Ratio | 1.4 |
| Total Assets | SAR 4.4B |
Price & Trading
| Last Close | SAR 31.22 |
| 50-Day MA | SAR 31.25 |
| 200-Day MA | SAR 29.65 |
| Avg Volume | 507K |
| Beta | 0.4 |
|
52-Week Range
SAR 24.96
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-10-10 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Saudi Chemical (2070)
Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments. The company is involved in the sale, marketing, and distribution of pharmaceutical, veterinary, medical equipment, and cosmetics products; and operates and maintains a secondary care hospital. In addition, it manufactures human medicines, and wholesales and retails of medicines and related products. Further, the company engages in the research and development of medical science activities, and investment business in related industries. The company was incorporated in 1986 and is headquartered in Buraydah, the Kingdom of Saudi Arabia.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Saudi Chemical (2070) halal to invest in?
The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Saudi Chemical's debt ratio?
Saudi Chemical's debt ratio is 32.8% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Saudi Chemical's key financial metrics?
Saudi Chemical has a market capitalization of SAR 3636M in its listing currency, trailing P/E ratio of 17.0, and revenue of SAR 1.7B. The company maintains a gross margin of 50.3% and a net margin of 12.3%. Return on equity stands at 12.7%.
How often is the screening data updated?
Calculation date: 2026-10-15. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.